💉 Semaglutide Cardiovascular Outcome Trial Simulator

Trial Population & Randomization

Placeholder: broad CVD-plus-obesity cohort, diabetes not required for entry.

• 17,604: Patients randomized (placeholder cohort size)
• 41 / ~800: Countries / sites (placeholder global reach)
• ≥27: BMI entry criterion (placeholder threshold)
• No: Diabetes required (placeholder key criterion)

Who was enrolled

Placeholder: adults 45+, established CVD, overweight or obese.

Randomization design

Placeholder: 1:1 semaglutide 2.4mg vs placebo, double-blind.

Why non-diabetic matters

Placeholder: isolates CV benefit from glycemic control effects.

Placeholder: broadens relevance beyond diabetes-only prior trials.

Treatment Period & Weight Trajectory

Placeholder: semaglutide arm sheds weight steadily; placebo stays flat.

• -9.4%: Weight Δ semaglutide (wk65) (placeholder trial mean)
• -0.9%: Weight Δ placebo (wk65) (placeholder trial mean)
• 16 wks: Dose titration (placeholder schedule)
• 2.4 mg: Maintenance dose (placeholder weekly SC)

GLP-1 mechanism

Placeholder: appetite suppression via hypothalamic GLP-1 receptor agonism.

Divergence timeline

Placeholder: separation visible by month 2, plateaus later.

Placebo arm behavior

Placeholder: standard-of-care only, minimal weight change.

Blood Pressure, Lipids & Inflammation

Placeholder: cardiometabolic markers improve alongside weight loss.

• -38%: hs-CRP Δ semaglutide (placeholder relative change)
• -3.8 mmHg: Systolic BP Δ (placeholder mean drop)
• -8.2 cm: Waist circumference Δ (placeholder mean drop)
• Improved: Lipid panel (placeholder direction)

Inflammation marker

Placeholder: CRP falls faster and further on treatment.

Blood pressure trend

Placeholder: modest systolic reduction tracks weight loss.

Mechanistic link

Placeholder: risk factor shifts plausibly mediate CV benefit.

Placeholder: benefit appears partly independent of weight loss alone.

MACE Accumulation Over Follow-up

Placeholder: event curves separate gradually across ~40 months.

• 39.8 mo: Median follow-up (placeholder duration)
• MACE: Primary endpoint (CV death, MI, stroke)
• 6.5%: Events, semaglutide (placeholder cumulative)
• 8.0%: Events, placebo (placeholder cumulative)

Composite endpoint

Placeholder: CV death, nonfatal MI, nonfatal stroke combined.

Kaplan-Meier separation

Placeholder: curves diverge early and widen over time.

Consistency across subgroups

Placeholder: benefit broadly consistent regardless of baseline weight.

Statistically Significant Risk Reduction

Placeholder: semaglutide lowers MACE risk independent of diabetes status.

• 0.80: Hazard ratio (placeholder 95% CI 0.72–0.90)
• ~20%: Relative risk reduction (placeholder headline result)
• <0.001: P-value (placeholder significance)
• NEJM 2023: Publication (placeholder citation)

Headline result

Placeholder: ~20% relative MACE reduction versus placebo.

Diabetes-independent benefit

Placeholder: effect held regardless of glycemic status.

Placeholder: expands GLP-1 cardioprotection beyond diabetic populations.

Clinical implication

Placeholder: obesity itself becomes a treatable CV risk target.

Open questions

Placeholder: durability, mechanism weighting, and access remain under study.